Last reviewed · How we verify
NCT06355024
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2 trial testing Inosine in Triple-negative Breast Cancer in 10 participants. Completed in 1 January 2025.
1 January 2025
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 11 May 2024 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Inosine (INOSINE) — full drug profile →
- Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum — full drug profile →
Conditions studied
- Triple-negative Breast Cancer — all drugs for Triple-negative Breast Cancer →
Sponsor
Fudan University
Who can join
Adults 18 to 70, female only, with Triple-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies.
Li J, Hu J, Yang Y, Zhang H, et al · · 2025 · cited 5× · PMID 41247642 · DOI 10.1186/s43556-025-00352-w
Verify or expand the search:
- PubMed search for NCT06355024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Inosine
Trials testing the same drug.
- NCT07170475 — A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease · Phase 1 · recruiting
- NCT04476238 — Inosine Energy Expenditure Study · NA · completed
- NCT03168711 — Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) · Phase 2 · completed
Other recruiting trials for Triple-negative Breast Cancer
Currently open trials in the same condition.
- NCT07510802 — Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC · Phase 1, PHASE2 · recruiting
- NCT07045311 — JS207 Combination Therapy in Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT06078384 — Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC · Phase 2 · recruiting
- NCT06817525 — Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC · Phase 2 · recruiting
- NCT06371274 — A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. · NA · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06355024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06355024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing